A detailed history of Marshall Wace, LLP transactions in Eli Lilly & CO stock. As of the latest transaction made, Marshall Wace, LLP holds 910,132 shares of LLY stock, worth $679 Million. This represents 1.04% of its overall portfolio holdings.

Number of Shares
910,132
Previous 789,561 15.27%
Holding current value
$679 Million
Previous $715 Million 12.8%
% of portfolio
1.04%
Previous 0.99%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$772.14 - $960.02 $93.1 Million - $116 Million
120,571 Added 15.27%
910,132 $806 Million
Q2 2024

Aug 14, 2024

BUY
$724.87 - $909.04 $265 Million - $333 Million
366,271 Added 86.53%
789,561 $715 Million
Q1 2024

May 15, 2024

SELL
$592.2 - $792.28 $176 Million - $236 Million
-297,256 Reduced 41.25%
423,290 $329 Million
Q4 2023

Feb 14, 2024

BUY
$525.19 - $619.13 $66.4 Million - $78.3 Million
126,477 Added 21.29%
720,546 $420 Million
Q3 2023

Nov 14, 2023

BUY
$434.7 - $599.3 $216 Million - $298 Million
497,640 Added 516.07%
594,069 $319 Million
Q2 2023

Aug 14, 2023

SELL
$350.74 - $468.98 $208 Million - $278 Million
-592,667 Reduced 86.01%
96,429 $45.2 Million
Q1 2023

May 15, 2023

BUY
$310.63 - $364.82 $172 Million - $202 Million
553,096 Added 406.69%
689,096 $237 Million
Q4 2022

Feb 14, 2023

SELL
$321.55 - $374.67 $85 Million - $99 Million
-264,245 Reduced 66.02%
136,000 $49.8 Million
Q3 2022

Nov 14, 2022

SELL
$296.48 - $337.87 $217 Million - $248 Million
-733,148 Reduced 64.69%
400,245 $129 Million
Q2 2022

Aug 15, 2022

BUY
$278.73 - $327.27 $316 Million - $371 Million
1,133,393 New
1,133,393 $367 Million
Q1 2022

May 16, 2022

SELL
$234.69 - $291.66 $501,532 - $623,277
-2,137 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$224.85 - $279.04 $34.1 Million - $42.3 Million
-151,748 Reduced 98.61%
2,137 $591,000
Q3 2021

Nov 15, 2021

BUY
$221.6 - $272.71 $13.2 Million - $16.2 Million
59,571 Added 63.16%
153,885 $35.6 Million
Q2 2021

Aug 13, 2021

BUY
$180.55 - $233.54 $13.4 Million - $17.3 Million
74,151 Added 367.76%
94,314 $21.6 Million
Q1 2021

May 17, 2021

SELL
$164.32 - $212.72 $31.6 Million - $40.9 Million
-192,051 Reduced 90.5%
20,163 $3.77 Million
Q4 2020

Feb 16, 2021

BUY
$130.46 - $172.63 $3.55 Million - $4.7 Million
27,204 Added 14.7%
212,214 $35.8 Million
Q3 2020

Nov 16, 2020

BUY
$146.22 - $169.13 $3.2 Million - $3.7 Million
21,902 Added 13.43%
185,010 $27.4 Million
Q2 2020

Aug 13, 2020

BUY
$136.42 - $164.18 $22.2 Million - $26.8 Million
163,099 Added 1812211.12%
163,108 $26.8 Million
Q1 2020

May 15, 2020

BUY
$119.05 - $147.35 $476 - $589
4 Added 80.0%
9 $1,000
Q4 2019

Feb 14, 2020

BUY
$106.92 - $132.43 $534 - $662
5 New
5 $1,000
Q3 2018

Nov 14, 2018

SELL
$85.86 - $107.31 $819,533 - $1.02 Million
-9,545 Closed
0 $0
Q2 2018

Aug 14, 2018

BUY
$75.7 - $86.88 $722,556 - $829,269
9,545 New
9,545 $814,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $709B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.